Suberoylanilide Hydroxamic Acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin

Journal of Cellular Biochemistry

Volumn 109, Issue 1, 2010, Pages 184-195

  Kuželová, Kateřina ^a   Pluskalová, Michaela ^a   Brodská, Barbora ^a   Otevřelová, Petra ^a   Elknerová, Klára ^a   Grebeňová, Dana ^a   Hrkal, Zbyněk ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Adhesion; Apoptosis; Hematopoietic cell; Integrin; Paxillin; Suberoylanilide hydroxamic acid

Indexed keywords

BETA1 INTEGRIN; BUTYRIC ACID; CASPASE 3; FIBRONECTIN; MESSENGER RNA; PAXILLIN; TRICHOSTATIN A; VORINOSTAT;

APOPTOSIS; ARTICLE; CELL ADHESION; CELL DEATH; CELL LINE; CELL STRAIN HL 60; CELL STRAIN K 562; CELL TYPE; CYTOSKELETON; DNA FRAGMENTATION; DRUG EFFECT; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

ANTIGENS, CD29; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL SEPARATION; FIBRONECTINS; FLOW CYTOMETRY; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA; LYMPHOCYTES; PAXILLIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 73849101542     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22397     Document Type: Article

References (48)

1. Aepfelbacher M. 1995. ADP-ribosylation of Rho enhances adhesion of U937 cells to fibronectin via the alpha 5 beta 1 integrin receptor. FEBS Lett 363:78-80.
2. Bernard O. 2007. Lim kinases, regulators of actin dynamics. Int J Biochem Cell Biol 39:1071-1076.
3. Bordin M, D'Atri F, Guillemot L, Citi S. 2004. Histone deacetylase inhibitors up-regulate the expression of tight junction proteins. Mol Cancer Res 2:692-701.
4. Brodská B, Otevřelová P, Kalousek I. 2009. Variations in c-Myc and p21WAF1 expression protect normal peripheral blood lymphocytes against BimEL-mediated cell death. Cell Biochem Funct 27:167-175.
5. Butler B, Gao C, Mersich AT, Blystone SD. 2006. Purified integrin adhesion complexes exhibit actin-polymerization activity. Curr Biol 16:242-251.
6. Chay K-O, Park SS, Mushinski JF. 2002. Linkage of caspase-mediated degradation of paxillin to apoptosis in Ba/F3 murine Pro-B lymphocytes. J Biol Chem 277:14521-14529.
7. Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD. 2008. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 19:964-969.
8. Desmond JC, Raynaud S, Tung E, Hofmann WK, Haferlach T, Koeffler HP. 2007. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia 21:1026-1034.
9. Dokmanovic M, Clarke C, Marks PA. 2007. Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 5:981-989.
10. Duvic M, Vu J. 2007. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Invest Drugs 16: 1111-1120.
11. Gao C, Schaefer E, Lakkis M, Blystone SD. 2005. Beta3 tyrosine phosphorylation and alphaVbeta3-mediated adhesion are required for Vav1 association and Rho activation in leukocytes. J Biol Chem 280:15422-15429.
12. Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C, Mufti GJ, Rassool FV. 2006. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis? Mol Cancer Res 4:563-573.
13. Gillenwater AM, Zhong M, Lotan R. 2007. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 6:2967-2975.
14. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. 2003. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151-163.
15. Grebeňová D, Kuželová K, Pluskalová M, Pešlová G, Halada P, Hrkal Z. 2006. The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells. Blood Cells Mol Dis 37:210-217.
16. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. 2004. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101:1241-1246.
17. Haberland M, Montgomery RL, Olson EN. 2009. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Gen 10:32-42.
18. Kabuyama Y, Langer SJ, Polvinen K, Homma Y, Resing KA, Ahn NG. 2006. Functional proteomics identifies protein-tyrosine phosphatase 1B as a target of RhoA signaling. Mol Cell Proteomics 5 (8): 1359-1367.
19. Kumagai T, Akagi T, Desmond JC, Kawamata N, Gery S, Imai Y, Song JH, Gui D, Said J, Koeffler HP. 2009. Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells. Int J Cancer 124:827-833.
20. Kuželová K, Grebeňová D, Pluskalová M, Marinov I, Klamová H, Hrkal Z. 2006. Imatinib mesylate affects tyrosine kinase activity in both leukemic and normal primary mononuclear blood cells. J Appl Biomed 4:95-104.
21. Kuželová K, Grebeňová D, Hrkal Z. 2007. Labeling of apoptotic JURL-MK1 cells by fluorescent caspase-3 inhibitor FAM-DEVD-fmk occurs mainly at site(s) different from caspase-3 active site. Cytometry Part A 71A:605-611.
22. Lai J-M, Hsieh C-L, Chang Z-F. 2003. Caspase activation during phorbol ester-induced apoptosis requires ROCK-dependent myosin-mediated contraction. J Cell Sci 116:3491-3501.
23. Lee HH, Chang ZF. 2008. Regulation of RhoA-dependent ROCKII activation by Shp2. J Cell Biol 181:999-1012.
24. Lindemann RK, Newbold A, Whitecross KF, Frew LA, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, Johnstone RW. 2007. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 104:8071-8076.
25. Mahlknecht U, Schönbein C. 2008. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. Haematologica 93:443-446.
26. Marks PA, Breslow R. 2007. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90.
27. Marks PA, Jiang X. 2005. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell cycle 4:549-551.
28. Meads MB, Hazlehurst LA, Dalton WS. 2008. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14:2519-2526.
29. Mitsiades CS, Mitsiades NS, Mcmullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC. 2004. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA 101:540-545.
30. Modesitt SC, Sill M, Hoffman JS, Bender DP. 2008. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 109:182-186.
31. Monneret C. 2005. Histone deacetylase inhibitors. Eur J Med Chem 40:1-13.
32. Nagamatsu Y, Rikitake Y, Takahashi M, Deki Y, Ikeda W, Hirata K, Takai Y. 2008. Roles of Necl-5/poliovirus receptor and Rho-associated kinase (ROCK) in the regulation of transformation of integrin alpha(V)beta(3)-based focal complexes into focal adhesions. J Biol Chem 283:14532-14541.
33. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks PA, Kelly WK. 2006. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173.
34. Peart MJ, Smyth GK, Van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, Johnstone RW. 2005. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:3697-3702.
35. Pellegrin S, Mellor H. 2007. Actin stress fibers. J Cell Sci 120:3491-3499.
36. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D. 2008. Phase I trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 49:502-507.
37. Riethdorf S, Wikman H, Pantel K. 2008. Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 123:1991-2006.
38. Rosato RR, Grant S. 2004. Histone deacetylase inhibitors in clinical development. Expert Opin Invest Drugs 13:21-38.
39. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. 2002. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer 99:292-298.
40. Schaller MD, Schaefer EM. 2001. Multiple stimuli induce tyrosine phosphorylation of the Crk-binding sites of paxillin. Biochem J 360:57-66.
41. Shao Y, Gao Z, Marks PA, Jiang X. 2004. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030-18035.
42. Shi J, Wei L. 2007. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp 55:61-75.
43. Tavares TS, Nanus D, Yang XJ, Gudas LJ. 2008. Gene microarray analysis of human renal cell carcinoma: The effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther 7:1607-1618.
44. Taylor RC, Cullen SP, Martin SJ. 2008. Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9:231-241.
45. Tong A, Zhang H, Li Z, Gou L, Wang Z, Wei H, Tang M, Liang S, Chen L, Huang C, Wei Y. 2008. Proteomic analysis of liver cancer cells treated with suberoylanilide hydroxamic acid. Cancer Chemother Pharmacol 61:791-802.
46. Villalonga P, Ridley AJ. 2006. Rho GTPases and cell cycle control. Growth Factors 24:159-164.
47. Xu WS, Parmigiani RB, Marks PA. 2007. Histone deacetylase inhibitors: Molecular mechanism of action. Oncogene 26:5541-5552.
48. Yu C, Dasmahapatra G, Dent P, Grant S. 2005. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia 19:1579-1589.